Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rabeprazole for GERD in adolescents aged 12 to 16 years
2016-001879-73Phase 2
- Sponsor
- Eisai Co., Ltd.
- Start
- Jun 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of rabeprazole in gastroesophageal reflux disease (GERD) (2 arms), sponsored by Eisai Co., Ltd. Primary endpoint: Number of participants with treatment-emergent adverse events and serious adverse events.
02
Drugs
rabeprazole
03
Conditions
gastroesophageal reflux disease (GERD)
Beyond the preview
Go deeper on 2016-001879-73.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-001879-73.